Report Detail

Pharmaceuticals & Healthcare Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2019

  • RnM3868735
  • |
  • 22 July, 2020
  • |
  • Global
  • |
  • 2766 Pages
  • |
  • Global Markets Direct
  • |
  • Pharmaceuticals & Healthcare

Table of Contents


      Glioblastoma Multiforme (GBM) - Overview

        Glioblastoma Multiforme (GBM) - Therapeutics Development

          Glioblastoma Multiforme (GBM) - Therapeutics Assessment

            Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development

              Glioblastoma Multiforme (GBM) - Drug Profiles

                Glioblastoma Multiforme (GBM) - Dormant Projects

                  Glioblastoma Multiforme (GBM) - Discontinued Products

                    Glioblastoma Multiforme (GBM) - Product Development Milestones


                      Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2020


                      Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme - Pipeline Review, H1 2020, provides an overview of the Glioblastoma Multiforme (Oncology) pipeline landscape.

                      Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

                      Report Highlights

                      Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                      The Glioblastoma Multiforme (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 130, 94, 2, 13, 198, 43 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 14, 14, 3, 53 and 9 molecules, respectively.

                      Glioblastoma Multiforme (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

                      Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


                      - The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (Oncology).
                      - The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
                      - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
                      - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
                      - The pipeline guide reviews key companies involved in Glioblastoma Multiforme (Oncology) therapeutics and enlists all their major and minor projects.
                      - The pipeline guide evaluates Glioblastoma Multiforme (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
                      - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
                      - The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (Oncology)

                      Reasons to Buy

                      - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
                      - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
                      - Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (Oncology).
                      - Classify potential new clients or partners in the target demographic.
                      - Develop tactical initiatives by understanding the focus areas of leading companies.
                      - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
                      - Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (Oncology) pipeline depth and focus of Indication therapeutics.
                      - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
                      - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

                      Get latest Market Research Reports on Glioblastoma Multiforme (GBM). Industry analysis & Market Report on Glioblastoma Multiforme (GBM) is a syndicated market report, published as Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Glioblastoma Multiforme (GBM) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                      Last updated on

                      REPORT YOU MIGHT BE INTERESTED

                      Purchase this Report

                      Credit card Logo

                      Related Reports

                      Reason to Buy

                      Request for Sample of this report